Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Lowered to Strong Sell Rating by Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research analysts have also recently commented on the stock. Wells Fargo & Company upped their target price on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Citigroup raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $39.56 on Tuesday. Kiniksa Pharmaceuticals International has a 1-year low of $18.12 and a 1-year high of $44.42. The business’s fifty day moving average price is $41.34 and its two-hundred day moving average price is $36.60. The firm has a market capitalization of $3.00 billion, a PE ratio of 87.91 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same period last year, the firm posted ($0.18) EPS. The business’s revenue was up 61.2% compared to the same quarter last year. Equities research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 50,490 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer directly owned 27,046 shares of the company’s stock, valued at $1,051,278.02. The trade was a 65.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sanj K. Patel sold 121,248 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.90, for a total transaction of $4,716,547.20. Following the completion of the sale, the chief executive officer owned 111,794 shares in the company, valued at approximately $4,348,786.60. This trade represents a 52.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 510,689 shares of company stock valued at $20,009,290. Corporate insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $20,349,000. Qube Research & Technologies Ltd lifted its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after buying an additional 447,536 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Kiniksa Pharmaceuticals International by 288.6% during the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after buying an additional 402,078 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.